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Abstract
Meniere’s disease represents one of the most frequent vestibulopathy, with 
prevalence of 46–200 cases per 100,000, without difference between genders and 
manifests in fourth decade of life. Features include dizziness/vertigo, hearing loss, 
tinnitus, and ear fullness. Individuals with Meniere’s disease have poor quality of life 
due to dizziness, regarding physical, functional, and emotional aspects. The thera-
peutic measures are proposed, depending on the stage of the disease. About 95% of 
the patients are well controlled with conservative clinical treatment. The remaining 
5% have incapacitating symptoms. These patients are candidates for surgical treat-
ments classics, decompression of the endolymphatic sac, vestibular neurectomy, or 
labyrinthectomy. Intratympanic gentamicin injections emerged as an alternative to 
surgical treatments, whose risk and benefit ratio has been shown to be much more 
satisfactory. Aminoglycosides, such as gentamicin have been used since the decade 
of 1950 for the vestibular chemical ablation in cases of intractable vertigo. The 
drawback is that gentamicin causes irreversible destruction to cochlear hair cells with 
hearing loss. The selective vestibulotoxicity in the treatment of Meniere’s disease can 
be used in the treatment of the vertigo promoting a chemical labyrinthectomy.
Keywords: Meniere’s disease, vestibulopathy, vertigo treatment,  
chemical labyrinthectomy, vestibulotoxicity
1. Introduction
Meniere’s disease (MD) is a clinical entity characterized by episodic vertigo, 
fluctuant sensorineural hearing loss (SNHL), tinnitus, and a pressure sensation of 
the ear. It can happen uni- or bilaterally, and diagnosis is made clinically, according 
to the classification of the American Academy of Otolaryngology—Head and Neck 
Surgery, updated in 2015 (Table 1) [1, 2]. MD is a chronic condition affecting about 
190/100,000 patients in US, a general incidence about 50–200/100,000 per year, 
and a lower incidence of 17/100,000 per year in Japan [3].
The diagnosis of MD remains eminently clinical and its manifestations are 
widely variable. Many patients have audiological symptoms, some have mainly 
vestibular complaints and few patients have a combination of auditory and vestibu-
lar symptoms. The bilateral involvement can be observed in 10–50% of the patients, 
which leads to a condition difficult to treat and with unfavorable prognosis [4].
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Figure 1. 
Reissner’s membrane displaced in a temporal bone with hydrops (arrowheads).
Figure 2. 
Membranous structures displaced in MD. The arrowhead points the membranous structure called saccule, in 
different stages of hydrops (A, normal; B, slight; C, moderate; and D, severe). FN-facial nerve; S-stapes.
2. Otopathology
Prosper Meniere, who worked as a director of the first school for the deaf-mute in 
Paris, described in 1861, a combination of vertigo, imbalance, and hearing impairment 
reflecting an inner ear disease [1]. But, only in 1937, with the discovery of endolym-
phatic hydrops (EH) in human temporal bones by Yamakawa and Hallpike and Cairns, 
the pathologic displacement of Reissner’s membrane into the scala vestibuli—and so 
with the dilation of the scala media of the cochlea—was first stablished (Figure 1) [5].
Definite Two or more episodes of vertigo* plus audiometrically confirmed low- to medium-frequency 
SNHL in one ear on at least one occasion before, during, or after one of the episodes of vertigo; 
fluctuating aural symptoms** in the affected ear; not better accounted for by another vestibular 
diagnosis
Probable Two or more episodes of vertigo or dizziness, each lasting 20 min to 24 h; fluctuating aural 
symptoms** in the affected ear; other causes excluded
*Defined as spontaneous, rotational vertigo lasting 20 min to 12 h.
**Hearing, tinnitus, or fullness.
Table 1. 
Criteria of diagnosis of MD.
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Many other disorders can be related with hydrops, as aforementioned: tem-
poral bone fracture, otosclerosis, diabetes mellitus, syphilis, hormonal disorders, 
migraine, and others. Diseases that can cause MD are as follows: food allergy, 
dyslipidemia, and autoimmune diseases [3, 6]. These disorders can also affect inner 
ear composition and displace in various degrees other membranous structures, 
including saccule, utricle, and the ampullae of the semicircular canals (Figure 2) [5].
3. Audiological findings
Several tests and evaluation methods have been employed for the diagnosis of 
MD. These include audiological tests, vestibular, radiological, clinical, and biochemi-
cal parameters. However, the lack of a definitive diagnostic test makes the process of 
diagnosis sometimes longer or frustrating. For this reason, the professional should 
be well experienced in the decision of when and what test should be used for the 
diagnostic process and, especially, to know how to interpret the results [7].
Although MD is not a rare condition, there is a delay in the diagnosis. Probably 
this is due to factors such as the difficulty of the differential diagnosis between 
other inner ear diseases, mainly due to the occurrence of nonspecific symptoms in 
the early stages of the disease and the absence of specific tests, in addition to the 
floating characteristic of MD which hinders the interpretation of the tests [8].
Patients with hearing loss and balance disorders are commonly diagnosed as 
having MD, which sometimes characterizes a diagnostic error, due to the lack of 
specific diagnostic tests [7, 8].
The main objective of early diagnosis is the early intervention, aiming to reduce the 
frequency and intensity of the crisis of vertigo and, at the same time, to preserve the 
hearing and vestibular functions [7]. Nonetheless, it is common among patients with 
MD, psychological suffering and loss in quality of life due to the crisis of vertigo [9, 10].
Some procedures significantly collaborate for the diagnosis of MD; however, it 
is important to emphasize the correlation of clinical history and symptoms with the 
results of the behavioral evaluation and testing goals for the conclusion of the case. In 
MD, a progressive hearing loss occurs with disappearance of vertigo in 70% of cases.
In addition, the audiological evaluation is important in monitoring treatment, as 
in the case of chemistry labyrinthectomy with gentamicin.
Tonal threshold audiometry is the basic examination used in the process of 
diagnosis and follow-up of MD and has a decisive role in treatment decisions. The 
progressive sensorineural hearing loss, with impairment of low frequencies and the 
fluctuations, is typical result observed in MD.
The degree of hearing loss seems to be related to the stage of the disease and 
has a relationship with the symptomatic period. It is common for MD patients a 
sensorineural hearing loss to moderate to severe before or on the first diagnosis. 
The settings of the hearing loss may vary; the most common is the ascendant or 
inverted “U.” The flat configuration appears in more advanced stages of the disease. 
However, different audiometric results can be found and variations in the degree 
and configuration of hearing loss may be observed, depending on the stage of the 
disease. Although the low frequencies are generally more affected, hearing loss may 
be present in all frequencies when in an advanced state of the disease, configuring 
sometimes an audiogram with flat curve [11]. In this way, the diagnosis of MD 
should not be established in accordance with the configuration of the audiogram, 
because there is not a specific audiometric pattern [12]. There is no consensus in 
the literature that the auditory thresholds for pure tone should be investigated, 
including thresholds of air and bone conduction and, at least for the frequencies 
250 Hz–8 kHz. A difference ≥10 dB is accepted as the float hearing for the MD. 
Meniere’s Disease
4
Relationship was found between the occurrence of fluctuation and the severity or 
progression of the hearing loss. Authors report that the hearing losses affecting 
the averages (between 500 and 2000 Hz) and high frequencies (between 3000 
and 8000 Hz) suggest a worse prognosis than that one affects the low frequencies 
(between 125 and 500 Hz) [13]. The value of the results of the hearing evaluation 
by means of ATL has been shown to be significant, and the cochlear symptoms have 
been described in the literature as the most common initial sign of the disease and, 
many times, to appear before the vertigo.
The speech perception tests are also compromised. The percentage index of speech 
recognition (PISR) and the speech recognition threshold (SRT) are altered in MD 
[12, 13]. The average score of the PISR, when there is hearing loss can be around 56% 
or less if the MD is of long duration. In cases of unilateral hearing loss, percentages of 
PISR worst in relation to expected, considering the results of the auditory thresholds 
for pure tone. The speech in noise tests has helped in the intervention of the patients 
with MD; individuals with MD unilaterally submitted to simultaneous labyrinthec-
tomy have improvement in sound localization and in speech understanding with and 
without competitive noise [13]. Acoustic immittance measures course with a type A 
configuration tympanometry, although in some patients with severe hearing loss of 
long term may present tympanometry curve characteristic of tubal dysfunction. The 
acoustic reflex threshold decreases in cochlear pathologies due to recruitment, the 
difference between the acoustic reflex thresholds of the frequencies of 500, 1000, 
and 2000 Hz and the tonal auditory thresholds obtained by air, the same frequencies 
of 60 dB or less, and outcome goal that suggests the presence of cochlear pathology 
(recruitment) [13]. It is worth mentioning that the acoustic immittance measures can 
be very useful in the diagnosis of MD, in cases of MD floating and nonfloating and 
with respect to the prediction of endolymphatic hydrops reversible and irreversible.
Electrocochleography (ECochG) can be used for MD diagnosis. The presence of 
endolymphatic hydrops is determined by the enlargement of the summation poten-
tial (SP) in relation to the action potential (AP), reflecting an increase in relation 
SP/AP. The SP enlargement is more evident when the patient presents fullness and 
mild hearing loss. In the initial stages of the MD, the increase in the endolymphatic 
volume alters the hydromechanical properties of cochlear stretching medium scale 
and changing SP. The specificity of the relationship SP/AP is larger than the sensi-
tivity in MD. The increase of SP/AP relationship suggests the diagnosis of MD, but 
only in about 50% of the cases, the disease really exists [13].
4. Available treatments
The characteristics of the MD are well documented, as well as the treatments for 
this pathology. The available literature is focused to identify the etiology and how 
to clinically approach the symptomatic patient. The symptomatic treatment can be 
pharmacological and/or surgical.
The symptomatic treatment does not prevent the progression of the disease. This 
treatment may involve diet, vestibular therapy, and drug treatment [11]. In acute 
vertigo crisis, drugs that block the vestibular reflexes in the vestibule-cerebral shaft can 
be used. They are chlorpromazine, cinnarizine, promethazine, and diazepam [5, 14].
The endolymphatic hydrops found in MD is treated aiming to prevent its 
progression. In this way, there is a low sodium diet and use of diuretics, such as 
furosemide and hydrochlorothiazide [6].
Vasodilators are used for long-term treatment based on the fact that the hydrops 
can be caused by ischemia of the stria vascularis. Currently, the medical treatment 
of maintenance is betahistine with or without diuretic [6, 10].
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5. Symptomatic chemical-surgical treatment
Studies have shown that the toxic effects of aminoglycosides in the sensorineural 
epithelium of the inner ear, particularly in the labyrinth, can be considered as a 
therapy for MD [6, 10].
In cases of MD with bilateral vestibular symptoms is difficult to control and 
with important hearing loss, has already been given in the past to ablation of the 
maze with systemic aminoglycosides because they control the vertigo. However, 
the cumulative doses of aminoglycosides increase the risk of ototoxicity with 
permanent cochlear damage and the possibility of causing ataxia and oscillopsia. 
Currently, with the possibility of injecting substances via transtympanic route, the 
indications for systemic use of aminoglycosides are limited [15].
6. Surgical treatment
In about 70% of the cases, MD evolves to progressive hearing loss with improve-
ment to the vestibular symptoms. For the other 30% who do not present an 
improvement of vestibular symptoms, even with the clinical treatment, surgical 
treatment should be thought.
The decision to operate and the choice of procedure are often dictated by the 
understanding and experience of each surgeon [3]. Surgical treatment to be considered 
varies from conservative to destructive, depending on whether or not there is a hearing 
loss [3]. The surgery that is the most popular is the endolymphatic sac decompression, 
and it is known as a conservative surgical procedure and is widely accepted.
This surgery was first described by Portmann, in 1927, but the precise role by 
which the surgery works remains undefined [16]. Among the destructive surgical 
treatments, we have a vestibular neurectomy, the cochleo-sacculotomy, the transca-
nal labyrinthectomy, or postauricular labyrinthectomy [4].
7. Transtympanic treatment
The use of systemic aminoglycosides was replaced by intratympanic gentamycin 
instillations that are administered once a day by a limited number of days. The 
intratympanic administration of drugs for the treatment of the MD was primarily 
described by Schuknecht in 1957 [17]. The intratympanic injections of gentamicin 
provide a high rate of success in the control of vertigo with reduced number of side 
effects on hearing [18, 19].
The intratympanic injections of gentamicin were proposed by Stokroos. After 
anesthesia of the tympanic membrane, gentamicin is administered in the middle ear 
through a fine needle of lumbar puncture in a fixed dose of 30 mg/ml [20, 21].
One other substance that can be used is steroid, which may decrease the inflam-
matory reaction in the inner ear, thus decreasing the endolymphatic hydrops. It 
has been reported that the use of corticosteroids may help to control the inner ear 
dysfunction, thereby decreasing vestibular symptoms up to 91% of MD patients 
(with 1–4 injections of dexamethasone at a concentration of 12 mg/ml) [22, 23].
Another substance to be injected is methylprednisolone, with higher concen-
trations and with the possibility to last longer in the perilymph. However, many 
authors described data suggesting same effectiveness of both steroids [24, 25].
Both gentamicin and steroids are absorbed by perilymph through the round 
window membrane (which is semipermeable), the annular ligament of the oval 
window, and by the small lacunar mesh that surrounds the inner ear [25].
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A randomized, double-blind controlled study compared the use of trans-
tympanic gentamicin (40 mg/ml) and corticosteroids (methylprednisolone 
[62.5 mg/ml]), and no difference was observed regarding the effectiveness of 
both groups of treatments [26].
8. Injection protocols
1. Patient positioned at supine position;
2. Head is positioned in a slightly hyper-extension with 30o contralateral rotation;
3. Instillation 2% lidocaine in ear canal, removing completely after 15 min;
4. Under microscopic examination, tympanic membrane is anesthetized with 
80–90% phenol solution at inferior and posterior tympanic membrane quadrant;
5. In few minutes, the transtympanic access could be performed using a spinal 
needle and a flexible catheter mounted on an insulin syringe;
6. Slow instillations of 1 ml of 26–40 mg/ml, not buffered with bicarbonate 
sodium in two 0.5 ml injection with 30 min apart;
7. Patient remained motionless for 30 min.
This protocol can be repeated each week or monthly for six times.
To maintain auditory function, patients must be evaluated with tone pure audi-
ometry on every 2 weeks or before beginning each section. The treatment must be 
stopped in case of hearing thresholds becoming higher than 10 dB or in a case of 
decreasing in speech audiometry of more than 15%. A supportive drug treatment 
may be necessary until the vertigo control. A pretreatment auditory test is very 
important. The bone conduction pure tone thresholds average (0.5, 1.0, 2.0, and 
3.0 kHz) is considered and repeated every 2 weeks and 2 weeks after treatment. 
The final audiometric exam is performed up to 12 months after transtympanic 
protocol initiation.
The success rate in transtympanic injection of gentamicin is about 87% in 
vertigo control, being a simple and safe procedure with few risks to hearing loss and 
tympanic membrane perforation [24, 27].
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